Q1 Net Loss Widens to $27.7M Amid CAR-T Acquisition; New $2.3M Liquidity Relief from Related Party
TPST sits 28% above its 52-week low of $1.5.
Summary
Tempest Therapeutics reported a $27.7 million net loss for Q1 2026 and reiterated a 'going concern' warning, but secured $2.3 million in new liquidity relief from a related party and completed a $2.0 million private placement.
Key Events · Financing and Capital Events · TPST
-
Going Concern Warning Reiterated
The company reported only $1.8 million in cash and cash equivalents as of March 31, 2026, down from $7.7 million at December 31, 2025, and expects its existing cash to fund operations for less than 12 months, raising substantial doubt about its ability to continue as a going concern.
-
Significant Net Loss Driven by Acquisition Costs
Net loss for Q1 2026 increased to $27.7 million, compared to $10.9 million in Q1 2025. This was primarily due to a $22.2 million non-cash expense for acquired in-process research and development related to the Erigen CAR-T asset acquisition.
-
New Liquidity Relief from Related Party
Subsequent to quarter-end, on May 11, 2026, Factor Bioscience Inc. (a related party) permanently waived $2.1 million in service fees and agreed to return a $0.2 million deposit, providing $2.3 million in immediate liquidity relief.
-
Private Placement Completed
In March 2026, the company raised $2.0 million in gross proceeds from a private placement, issuing common stock and warrants. This offering also has the potential to generate up to an additional $4.0 million upon cash exercise of the common warrants.
Analysis · TPST · Life Sciences
Tempest Therapeutics reported a substantial net loss for Q1 2026, primarily due to a significant non-cash expense related to its strategic CAR-T asset acquisition. The company continues to operate under a 'going concern' warning, highlighting its precarious financial position with only $1.8 million in cash at quarter-end. However, new liquidity relief from a related party, Factor Bioscience Inc., provides a critical, albeit temporary, boost to the company's cash runway, alongside a recent private placement. This indicates ongoing efforts to secure funding and advance its pipeline despite severe financial challenges.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.